WHO Prequalifies Takeda's Second Dengue Vaccine on Wednesday

May 15, 2024, 07:27 PM

The World Health Organization (WHO) has prequalified a new dengue vaccine developed by Takeda Pharmaceuticals on Wednesday. This marks the second dengue vaccine to receive WHO prequalification, aiming to bolster efforts against the disease amid rising outbreaks, particularly in the Americas. The WHO recommends the vaccine for children aged 6 to 16 in areas with high dengue burden and transmission intensity. Dengue, a vector-borne disease transmitted by infected mosquitoes, affects over 100-400 million people globally each year.